Description

Relamorelin TFA (CAS No.?2863659-22-5), also known as RM-131 TFA or BIM-28131 TFA, is a synthetic pentapeptide analog of ghrelin. It acts as a selective agonist for the growth hormone secretagogue receptor (GHSR), specifically the GHS-1a subtype, with a Ki of 0.42 nM. Relamorelin TFA is centrally penetrant, meaning it can cross the blood-brain barrier, and has been shown to increase growth hormone levels and accelerate gastric emptying.

This compound has potential applications in the treatment of conditions such as cachexia, gastroparesis, and other gastric/intestinal dysmotility disorders. It has been studied for its ability to stimulate appetite and promote food intake, making it a valuable tool in gastrointestinal motility research.

Manufactured under GMP standards with a purity of 99.81%, Relamorelin TFA ensures consistency and reliability for experimental use. It is available in various quantities to suit research needs.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action:
Relamorelin TFA is a synthetic analog of ghrelin that selectively activates the GHS-1a receptor. It has approximately three times the affinity (Ki = 0.42 nM) and six times the potency (EC50 = 0.71 nM) of native ghrelin in activating this receptor. Its ability to cross the blood-brain barrier allows it to influence central and peripheral pathways involved in appetite regulation and gastric motility.

Research Applications:

• Gastrointestinal Motility Disorders: Investigating treatments for conditions like gastroparesis and chronic constipation.

• Cachexia Studies: Exploring potential therapies for weight loss and muscle wasting associated with chronic illnesses.

• Appetite Regulation: Studying mechanisms of appetite stimulation and feeding behavior.

• Growth Hormone Secretion: Understanding the role of ghrelin receptor agonists in growth hormone release.

  

Side Effects (Research Context Only)

Relamorelin TFA is intended for laboratory research use only. In preclinical studies, it has been shown to increase food intake and body weight without significant adverse effects. However, as with all experimental compounds, appropriate safety protocols should be followed during handling and administration.

Disclaimer

Relamorelin TFA is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Users should adhere to institutional safety guidelines and regulatory requirements when handling this compound.